开发皮内DNA疫苗递送策略以实现针对呼吸道合胞病毒的单剂免疫
评估基于SynCon® DNA疫苗编码改造RSV-F抗原、经表面电穿孔装置皮内递送以靶向表皮细胞的疫苗接种策略,在棉鼠RSV/A攻击模型中单剂低剂量即可诱导强免疫应答并完全抵抗肺部感染,且与甲醛灭活RSV疫苗不同,未出现感染后肺部炎症加重。
要点
- 皮内递送SynCon® DNA疫苗编码改造RSV-F抗原可诱导强免疫应答。
- 棉鼠RSV/A攻击模型中单剂低剂量疫苗实现完全抵抗肺部感染。
- 与甲醛灭活RSV疫苗不同,DNA疫苗接种后病毒攻击未出现肺部炎症加重。
核心结论
- 数据概述了一种高效、可耐受且安全的非复制型疫苗递送策略的临床前开发。
研究设计与样本
- 基于SynCon® DNA疫苗编码改造RSV-F抗原,使用表面电穿孔装置皮内递送至表皮细胞,在临床相关实验模型中评估。
主要发现
- 该策略可诱导强免疫应答。
- 棉鼠RSV/A攻击模型中单剂低剂量疫苗实现完全抵抗肺部感染。
- 与甲醛灭活RSV疫苗相比,DNA疫苗接种后病毒攻击未出现肺部炎症加重。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Respiratory syncytial virus (RSV) is a massive medical burden in infants, children and the elderly worldwide, and an effective, safe RSV vaccine remains an unmet need. Here we assess a novel vaccination strategy based on the intradermal delivery of a SynCon® DNA-based vaccine encoding engineered RSV-F antigen using a surface electroporation device (SEP) to target epidermal cells, in clinically relevant experimental models. We demonstrate the ability of this strategy to elicit robust immune responses. Importantly we demonstrate complete resistance to pulmonary infection at a single low dose of vaccine in the cotton rat RSV/A challenge model. In contrast to the formalin-inactivated RSV (FI-RSV) vaccine, there was no enhanced lung inflammation upon virus challenge after DNA vaccination. In summary the data presented outline the pre-clinical development of a highly efficacious, tolerable and safe non-replicating vaccine delivery strategy.
引用
- Smith TRF, Schultheis K, Morrow MP, et al. Development of an intradermal DNA vaccine delivery strategy to achieve single-dose immunity against respiratory syncytial virus. Vaccine. 2017. PMID: 28413132. doi:10.1016/j.vaccine.2017.04.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。